



VASUDHA PHARMA CHEM LIMITED

Contributing to Affordable HealthCare ...

Exports
90+
COUNTRIES



BRAZIL

MEXICO

CANADA

EUROPE

JAPAN

USA

MIDDLE EAST

INDIA

CHINA



DIGITAL CATALOGUE

ACCREDITATION



www.vasudhapharma.com

Vasudha Pharma Chem Limited (VPCL) was founded by Sri. **M.V.Rama Raju, Chairman & Managing Director, (CMD)** in 1994. Commenced commercial production in the year 1996. The organisation is involved in the manufacturing of Piperidone & Piperidine derivatives, Intermediates, APIs and Pellets. The manufacturing facilities of the company have been audited by several international regulatory authorities: USFDA, EDQM, PMDA, ANVISA COFEPRIS (Mexican MOH), Korean FDA, Russian FDA, NMPA, CANADA and WHO GMP.

M V Rama Raju – Chairman & Managing Director

- Founder of “Vasudha Foundation” (2004)
- VRRV Family Vasudha Foundation (Sec. 8. Co.), 2024
- Trustee & Executive Committee Member Kasturba Gandhi National Memorial Trust (Indore, INDIA)

A post graduate in Organic Chemistry with around 41 years of rich experience in the manufacture of Active Pharmaceutical Ingredients (APIs). He is a technocrat in the Pharmaceutical Industry and started his career in the South India Research Institute (SIRIS), 1972-76. Arvind Chemicals in 1976 for manufacturing of intermediates and Hyfabs in 1979 for the fabrication of chemical equipment. He was also founder and Managing Director of Hicel Pharma (P) Ltd, manufacturing Analgin during 1984-89. Finally he established Vasudha Pharma Chem Limited (VPCL) in 1994-95 and he has been the Managing Director of the organization since inception. Present stature and reputation of the organization is because of his vision, perseverance, active involvement in production, product development, marketing strategies, capacity expansion and upgradation of facilities to cGMP standards.

Vasudha Pharma Chem Limited (VPCL) major milestones are listed below :

Major Milestones of VPCL Unit - I

1994 : Established
1997 : Drug License received from DCA, Telangana State, India.
2003 : WHO GMP Certified.
2013 : EU-WC Grant from CDSCO, Delhi.

Since Established :

- Inspected by US FDA , Mexican MOH (COFEPRIS), MFDS, EU-WC received from CDSCO - India, PMDA EDQM, RUSSIAN GMP,
- Eco Vadis CSR rating Silver level (Nov, 2018), Bronze level (Oct, 2020), Silver level (Apr, 2022)
- 2021: EDQM (REAL TIME REMOTE INSPECTION)
- 2022: ISO14001:2015; 45001:2018
- 2022: Process Safety Management Program (PSM) introduced and under implementation
- 2025: Inspected by USFDA from March 10th to 14th

Major Milestones of VPCL Unit - II

2007 : Commenced the Operations.
2007 : Drug License received from DCA, Andhra Pradesh State, India.
2009 : WHO GMP Certified.
2013 : EU-WC Grant from CDSCO, Delhi

Since Established :

- Inspected by USFDA, KFDA, Mexican MOH (COFEPRIS), PMDA, EDQM, ANVISA
- 2021 : ISO 14001:2015; 45001:2018, Eco Vadis CSR rating - Bronze level (Nov, 2021),
- 2020 : PMDA, Japan accreditation received for Domperidone and Domperidone Maleate.
- 2022 : Process Safety Management Program (PSM) introduced and under implementation
Renewal of EU-WC from CDSCO, India, Inspection held from 7th & 8th April 2022.
- 2022 : NDA of Uganda inspected in the month of 30th & 31st May 2022 and Certificate received in the month of Jan 2023
- 2023 : Received EDQM Certificate
- 2024 : Eco Vadis CSR Rating : Bronze level Published on 29-05-2024 valid until 29-05-2025.
: Approved by USFDA from September 9th to 13th.
: Approved by ANVISA from October 28th to November 1st.
- 2025 : Inspected by CFDA from February 24th to 28th.



Major Milestones of VPCL Unit - III

- 2011 : Commenced the Operations.
- 2012 : Drug License received from DCA, Andhra Pradesh State, India.
- 2016 : WHO GMP Certified.
- 2014 : EU-WC Grant from CDSCO, Delhi

Since Established :

- Inspected by USFDA, KFDA, PMDA, ANVISA.
- 2017 ISO EMS 14001:2015BS Certified with ISO 45001 : 2018 Certified.
- Approved by US FDA & KFDA.
- 2021: Process Safety Management Program (PSM) introduced & under implementation
- 2023 : Successfully achieved ANVISA renewal ; ISO 14001: 2015 & ISO 45001 : 2015 renewal
- 2024 : Successfully achieved PMDA Certificate / EU-WC renewal for the API's

Major Milestones of VPCL Unit - IV

- 2016 : Commenced Operations
Received Drug License in 2016 License # : 11/VSP/AP/2016/F/R Valid up to 07/08/2026
- 2022 : Achieved WHO GMP Certificate in 2022 #: HMF07-14051/2017/2021-ADMIN-DCA- 02/05/2022
Valid up to 01/05/2025

Major Milestones of VPCL Unit - V

- 2019 : Commenced the Operations.
- 2019 : Drug License received from DCA, Andhra Pradesh State, India.
- 2021 : WHO GMP Certified.
- 2024 : EU-WC Grant from CDSCO, Delhi

Since Established :

- 2020 ISO EMS 14001: 2015 & ISO 45001: 2018 Certified.
- 2022: CEP certificate for the product of "Olmesartan Medoxomil" & "Process Safety Management" (PSM) introduced & Under implementation

Vasudha Pharma Chem Limited (VPCL) Accreditation :

India Ratings & Research (A Fitch Group Company) latest Rating on VPCL's Bank Facilities:

- Fund-based Working Capital Limits: IND A+/Stable/IND A1+
- Non-fund-based Working Capital Limits: IND A1+ with effect from 21-02-2025.
- DUNS & Bradstreet Rating : 5A2
- Government of India Accredited with 4 Star (★★★★) Export house certificate and also we are AEO T3 Certified Company.

Our Vision is to achieve sustainable & quality growth

- **Planet** : Want to be a responsible global citizen by helping & supporting ecological communities.
- **People** : VPCL to be a great work place, where human values are respected & people get inspired.
- **Portfolio** : Offering quality products across the globe satisfying the requirements of regulators and global pharma companies.
- **Productivity** : Achieving best productivity by continuous skill enhancement and technology upgradation.
- **Partners** : Creating a supportive network of customers & suppliers, jointly enhancing the value of the business.



ACTIVE PHARMACEUTICAL INGREDIENTS (APIs)

Product Name	Specifications	DMF Status	CAS #
Amitriptyline HCl	IP/USP/BP/Ph.Eur/JP	USDMF/CEP/KDMF/CANADA	549-18-8
Aripiprazole	IP/USP/Ph.Eur	CEP Applied	129-722-12-9
Cisapride Monohydrate	USP	USDMF/ASMF	260779-88-2
Cinnarizine	Ph.Eur/USP/IP	CEP	298-57-7
Clopidogrel Bisulphate	IP/USP/BP/Ph.Eur/JP	USDMF/CEP	120202-66-6
Cyclobenzaprine HCl	USP/IP	USDMF/ASMF/KDMF/CADIFA/CANADA	6202-23-9
Cyproheptadine HCl	IP/USP/BP/Ph.Eur	USDMF/CDMF/ CEP Applied	41354-29-4
Dabigatran Etexilate Mesylate	Ph.Eur/USP	DMF / CEP Applied	872728-81-9
Desloratadine	USP/Ph.Eur/BP	USDMF/CEP/KDMF/CADIFA/CDMF	100643-71-8
Diatrizoic Acid	USP	USDMF	117-96-4
Diatrizoic Acid Dihydrate	USP/EP/IP	USDMF	50978-11-5
Diatrizoic Sodium	IP/USP	USDMF	737-31-5
Diatrizoic Meglumine	USP/IP	USDMF	131-49-7
Dimethyl Fumarate	In-House	USDMF	624-49-7
Diltiazem HCl	USP/Ph.Eur/IP	USDMF / CEP Applied	33286-22-5
Domperidone	IP/Ph.Eur/BP/JP/CP	CEP/JDMF/KDMF/CDMF	57808-66-9
Domperidone Maleate	IP/BP/Ph.Eur	CEP/KDMF	83898-65-1
Donepezil HCl	IP/USP/JP/Ph.Eur	JDMF	120011-70-3
Donepezil HCl Monohydrate	USP/Ph.Eur	USDMF/CEP Applied/KDMF	884740-09-4
Ebastine	Ph.Eur/BP/JP	CEP/BRAZIL DMF/ CADIFA	90729-43-4
Esomeprazole Magnesium Trihydrate	IP/USP/BP/Ph.Eur	USDMF/CEP/KDMF	217087-09-7
Febuxostat	In-House	DMF	144060-53-7
Fexofenadine HCl	IP/USP/BP/Ph.Eur/JP	USDMF/CEP/KDMF/CADIFA/CDMF	153439-40-8
Flurbiprofen	IP/USP/BP/Ph.Eur/JP	DMF	5104-49-4
Flunarizine Di HCl	USP/Ph.Eur/IP	CEP/KDMF/CDMF	30484-77-6
Itopride HCl	In-House/IP	KDMF/CDMF	122892-31-3
Itraconazole	USP/Ph.Eur/JP/CP	USDMF/CEP/JDMF/KDMF/CDMF	84625-61-6
Ketorolac Tromethamine	IP/USP/BP/Ph.Eur	USDMF/CEP/CADIFA	74103-07-4
Lacosamide	USP/Ph.Eur	CEP Applied	175481-36-4
Loperamide HCl	IP/USP/BP/Ph.Eur	USDMF/CEP/JDMF/CDMF	34552-83-5
Loratadine	USP/BP/Ph.Eur/IP	USDMF/CEP/CDMF/CADIFA/JDMF	79794-75-5
Losartan Potassium	IP/USP/BP/Ph.Eur/JP	USDMF/CEP/KDMF /CADIFA	124750-99-8
Mebeverine HCl	IP/IH/Ph.Eur/BP	CEP Applied	2753-45-9
Methoxyphenamine HCl	In-House	CDMF Applied	93-30-1

Patented products available for R & D use only and are permitted under 35 USC 271 (e).

Patented products cannot be offered to the countries where patent law is in force.

Final responsibility lies with the buyer exclusively.



ACTIVE PHARMACEUTICAL INGREDIENTS (APIs)

Product Name	Specifications	DMF Status	CAS #
Mirabegron	Ph.Eur	USDMF/CEP Applied	223673-61-8
Nortriptyline HCl	IP/BP/USP/Ph.Eur/JP	USDMF/CEP/CADIFA	894-71-3
Oxatomide Anhydrous	In-House	DMF/ASMF/JDMF	60607-34-3
Olmesartan Medoxomil	IP/USP/BP/Ph.Eur	USDMF/CEP	144689-63-4
Pantoprazole Sodium Sesquihydrate	IP/USP/BP/Ph.Eur	USDMF/CEP/KDMF/CADIFA/CANADA	164579-32-2
Pimozide	IP/USP/BP/Ph.Eur	USDMF/CEP	2062-78-4
Pimobendan	USP/Ph.Eur	DMF	74150-27-9
Pregabalin	IP/Ph.Eur/USP	USDMF/CEP/KDMF	148553-50-8
Quetiapine Fumarate	IP/USP/Ph.Eur/JP	USDMF/CEP	111974-72-2
Rivaroxaban	USP/Ph.Eur	USDMF/CEP	366789-02-8
Rupatadine Fumarate	IP/Ph.Eur/USP	USDMF/CEP/KDMF	182349-12-8
Tamsulosin HCl	IP/USP/BP/Ph.Eur	USDMF/CEP	106463-17-6
Telmisartan	IP/USP/BP/Ph.Eur	USDMF/CEP Applied	144701-48-4
Trazadone HCl	Ph.Eur/IP	CEP Applied	25332-39-2
Valsartan	USP/Ph.Eur/IP	DMF	137862-53-4
Vonoprazan fumarate	JP	DMF	881681-01-2

UNDER DEVELOPMENT (APIs)

Product Name	Specifications	DMF Status	CAS #
Bempezoic acid	In-House	UNDER DEVELOPMENT	738606-46-7
Bepotastine Basilate	JP		190786-44-8
Bilastine	IP		202189-78-4
Dapagliflozin Propanediol	USP		960404-48-2
Edoxaban Tosylate	In-House		480449-71-6
Iopromide	USP/EP/BP/IP		73334-07-3
Oxcarbazepine	USP/Ph.Eur		28721-07-5
Piribedil	In-House		3605-01-4
Sacubitril Sodium	USP		149690-05-1
Ticagrelor	Ph.Eur/IP		274693-27-5

Patented products available for R & D use only and are permitted under 35 USC 271 (e).

Patented products cannot be offered to the countries where patent law is in force.

Final responsibility lies with the buyer exclusively.



INTERMEDIATES

Product Name	Intermediate	CAS#
Alcaftadine	N-Methyl-4-chloro piperidine	5570-77-4
Amitriptyline HCl & Nortriptyline HCl	Dibenzosuberone	1210-35-1
	3-(N,N, di methyl amino) propylchloride HCl	5407-04-5
Bepotastine Besilate	N-carbethoxy-4-hydroxypiperidine	65214-82-6
	α -(4-Chlorophenyl) pyridine -2-methanol	27652-89-7
	2-((4-Chlorophenyl) (4-piperidinyl)oxy) methyl pyridine	122368-54-1
	4-Hydroxypiperidine	5382-16-1
	4-[(4-Chlorophenyl)-2-pyridylmethoxy]piperidine p-nitrobenzoic acid salt	161558-45-8
Brigatinib	1-methyl-4-(piperidin-4-yl)-piperazine	53617-36-0
Cinnarizine and Flunarizine	1-(Diphenyl methyl) piperazine	841-77-0
Cyclobenzaprine HCl	Dibenzosuberone	2222-33-5
	3-(N,N Di methyl amino) propylchloride HCl	5407-04-5
Cyproheptadine HCl	Dibenzosuberone	2222-33-5
	N-Methyl-4-chloro piperidine	5570-77-4
Dabigatran Etxilate Mesylate	3-[[[2-[[[4-Cyanophenyl]amino]methyl]-1-methyl-1H-benzimidazol-5-yl]carbonyl]pyridin-2-ylamino]propionic acid ethyl ester	211915-84-3
	N-[[2-[[[4-(Aminoiminomethyl)phenyl]amino]methyl]-1-methyl-1H-benzimidazol-5-yl]carbonyl]-N-2-pyridinyl-beta-alanine ethyl ester	429658-95-7
	Ethyl 3-(((2-(((4-(((hexyloxy) carbonyl) amino) iminomethyl) phenyl) amino)\methyl)-1-methyl-1H-benzimidazol-5-yl)\carbonyl) (pyridin-2-yl)amino) propanoate	211915-06-9
Domperidone	1-(3-Chloropropyl)-1,3-dihydro-1H-benzimidazol-2-one	62780-89-6
	5-Chloro 1,3 dihydro -1- (4-piperidinyl) -2H- benzimidazol - 2 -one	53786-28-0
Donepezil	4-[(5,6-Dimethoxy-1-indanon-2-yl) methyl] piperidine	120014-30-4
	5,6-dimethoxy-2-(pyridine-4-yl)-methylene-indan-1-one	4803-74-1
Donepezil (BASE)	(2RS)-2-[(1-Benzylpiperidin-4-yl)-5, 6-dimethoxy-2, 3- dihydro-1H-inden-1-one	120014-06-4
Ebastine	4-Tert butyl-4-chlorobutyrophenone	43076-61-5
Eprosartan	2-Butyl-1H-imidazole-5-carboxaldehyde	68282-49-5
Febuxostat	Ethyl 2-(4-hydroxyphenyl)-4-methyl thiazole-5-carboxylate	161797-99-5
	Ethyl 2-(3-formyl-4-hydroxyphenyl)-4-methylthiazole-5-carboxylate	161798-01-2
	Ethyl 2-(3-cyano-4-hydroxyphenyl)-4-methylthiazole-5-carboxylate	161798-02-3
	Ethyl-2-(3-Formyl-4-isobutoxy phenyl)-4-methyl-1,3-thiazole-5-carboxylate	161798-03-4
	Ethyl 2-(3-cyano-4-isobutoxyphenyl)-4-methylthiazole-5-carboxylate	160844-75-7
Flunarizine Di hydrochloride	1-[bis(4-fluorophenyl)methyl]piperazine	27469-60-9
Gadobutrol (Cyclen intermediate)	1,4,7,10-Tetraazacyclododecane	294-90-6
Golvatinib & Gilteritinib	1-N-Methyl-4-(4-piperidin-4-yl)-piperazine	53617-36-0
Haloperidol	4-Chloro-4'-fluoro-butyrophenone	3874-54-2
	4-(4-Chlorophenyl)-4-hydroxy piperidine	39512-49-7
Indoramin hydrochloride	4-Benzamido piperidine	194423-17-1
Ketotifen	N-Methyl-4-chloro-piperidine	5570-77-4
Linagliptin	(R)-3-(boc-amino) piperidine	309956-78-3
	(R)-3-Piperidinamine dihydrochloride	334618-23-4



INTERMEDIATES

Product Name	Intermediate	CAS#
Loperamide HCl	4-(4-Chlorophenyl)-4-hydroxy piperidine	39512-49-7
	N,N-Dimethyl(tera hydro-3,3-diphenyl)-2-furylidene ammonium bromide (furaninium bromide)	37743-18-3
	α,α -Diphenyl- γ -butyrolactone	956-89-8
	4-Bromo-2-(2-diphenylbutyric acid	37742-98-6
Loratadine & Desloratadine	3-[2-(3-Chlorophenyl) ethyl]-2-cyano pyridine	31255-57-9
	8-Chloro-5,6 dihydro(11H)-benzo[5,6] cyclohepta (1,2b) pyridine -11-one	31251-41-9
	8 Chloro-11-[(N-methyl)-4-piperidylidene]-6, 11-dihydro-5H-benzo [5,6]cyclohepta (1,2b) pyridine (methyl loratadine)	38092-89-6
	{3-[2-(3-Chlorophenyl)ethyl]pyridine-2-yl}-(1-methyl piperidine-4-yl) (methanone HCl)	119770-60-4
	N-Methyl-4-chloro piperidine	5570-77-4
Losartan Potassium	2-N-Butyl-4-chloro-1-[(2"-H tetrazol-5-yl)(1,1"- biphenyl)-4yl)methyl]-1H imidazole-5-methanol(losartan base)	11479-26-4
	2-Butyl-4-Chloro-5-Formylimidazole (BCFI)	83857-96-9
	(R)-N-(4-nitrophenethyl)-2-hydroxy-2-phenylacetamide	521284-19-5
Mirabegron	(R)-2-(4-nitrophenethylamino)-1-phenylethanol.HCl	521284-21-9
	(R)-2-(4-aminophenethylamino)-1-phenylethanol	521284-22-0
	1-(3-Chloropropyl)-1,3-dihydro-2H-benzimidazol-2-one	62780-89-6
Oxatomide	1-(Diphenyl methyl) piperazine	841-77-0
	4-[2-(2-Amino-4,7-dihydro-4-oxo-1h-pyrrolo[2,3-d] Pyrimidin-5-yl)ethyl] Benzoic Acid	137281-39-1
Pemetrexed	4-(2-Keto-1-benzimidazoliny) piperidine	20662-53-7
	1-Chloro-4,4-di (4-fluorophenyl)butane	3312-04-7
Prucalopride	1-(3-Methoxy propyl) piperidine-4-one	16771-85-0
	1-(3-Methoxypropyl)-4-Piperidinamine	179474-79-4
Rifabutin	1-Isobutyl-4-piperidone	72544-16-2
Rivaroxaban	4-[4-[(5S)-5-Phthalimidomethyl-2-oxo-3-oxazolidinyl]phenyl]-3-morpholinone	446292-08-6
	4-(4-((S)-5-(Aminomethyl)-2-oxooxazolidin-3-yl) phenyl)morpholin-3-one HCl	898543-06-1
Ropivacaine	(S)-N-(2,6-Dimethylphenyl)piperidine-2-carboxamide	27262-40-4
Rupatadine Fumarate	3-Chloromethyl-5-methyl pyridine HCl	1007089-84-0
Selexipag	4-(Isopropylamino)butanol	42042-71-7
Tamsulosin	R-(-)-5-(2-Amino-propyl)-2-methoxy-benzenesulfonamide	112101-81-2
	5-[2-[2-(2-Ethoxyphenoxy)ethylamino]propyl]-2-methoxy-benzenesulfonamide	106133-20-4
Trazadone	[1,2,4]triazolo[4,3-a]pyridin-3-one	6969-71-7
	"1-(3-chlorophenyl)-4-(3-chloropropyl)piperazine hydrochloride"	52605-52-4
Vonoprazan Fumarate	5-(2-Fluorophenyl)-1-(3-pyridinylsulfonyl)-1H-pyrrole-3-carboxaldehyde	881677-11-8
New Intermediate	N-(4-Amino-2-Cyanophenyl)-N,N-Dimethylmethanimidamide	194423-17-1



PIPERIDONE AND PIPERIDINE DERIVATIVES

N-METHYL PIPERIDONE DERIVATIVES :

- N-Methyl-4-piperidone (1445-73-4)
- N-Methyl-4-hydroxypiperidine (106-52-5)
- N-Methyl-4-chloropiperidine (5570-77-4)
- N-Methyl-4-chloropiperidine HCl (5382-23-0)
- N-Methyl-4-aminopiperidine (41838-46-4)
- N-Carbethoxy-4-piperidone (29976-53-2)
- N-Carbethoxy-4-hydroxypiperidine (65214-82-6)
- N-Carbethoxy-4-aminopiperidine (58859-46-4)

N-BENZYL PIPERIDONE DERIVATIVES :

- N-Benzyl -4-piperidone (3612-20-2)
- N-Benzyl -4-hydroxypiperidine (4727-72-4)
- 4-Benzyl -4-hydroxypiperidine (51135-96-7)
- N-Benzyl -4-chloropiperidine (67848-71-9)
- N-Benzyl-4-aminopiperidine (50541-93-0)
- 4-(2-Keto-benzimidazolyl) piperidine (20662 -53-7)

SPECIALISED PIPERIDONE DERIVATIVES :

- 4-Piperidone ethylene ketal (177-11-7)
- 4-Hydroxypiperidine (5382-16-1)
- 4-Aminopiperidine (13035-19-3)
- 4-Piperidinopiperidine (4897-50-1)
- 1,4'-Bipiperidine dihydrochloride (4876-60 -2)
- N-Piperidin-4-ylbenzamide (33953-37-6)
- N-l sobutyl -4-piperidone (72544-16-2)
- 1-(4 -Chlorobenzhydryl) -piperizine (303-26-4)
- N-Ethyl-4-piperidone (3612-18-8)
- 1,3 -dimethyl -4-piperidone (4629 -80-5)
- (R)-(-)-3- Aminopiperidine dihydrochloride (334618-23-4)
- N-Propyl -4-piperidone (23133-37-1)
- 3-Chloromethyl-5-Methylpyridine Hydrochloride (1007089-84-0)

GRIGNARD REACTION PIPERIDONE DERIVATIVES

- 4-(4-Chlorophenyl)-4-hydroxypiperidine (39512-49-7)
- 4-(4-Bromophenyl) -4-hydroxypiperidine (57988-58-6)
- 4-Phenyl-4-hydroxypiperidine (40807-61-2)
- 4-Phenylpiperidine (771-99-3)

RESEARCH and DEVELOPMENT (R&D)

Our R&D centre is a state of Art facility (area 8475 sq.ft) with 23 number of modernist Fume Hoods, fully equipped with advanced analytical instruments, having 114 number of highly qualified scientific resources who have capacity to handle diverse projects simultaneously.

Key Capabilities of R&D:

- Fastrack "Process Development" and "Technology Transfer" to site
- Non-infringing process identification and IP landscaping
- DOE-QbD based process development as per ICH guideline (CQA and CPP assessment)
- Rapid, stability indicating "Analytical Method Development"
- Impurity mining, isolation and characterization followed by spike and purge study
- Efficient data integration and efficient trouble shooting
- Process Engineering Assessment (Failure Mode Effective Analysis)
- Process safety and 'HAZOP' study Assessment
- Polymorph study
- Proactive backward integration of raw materials

These core competencies reflect our commitment to excellence, innovation, and delivering high-quality pharmaceutical products and services to our clients.

Our focus on effective planning, resource allocation, and risk management ensures successful project execution



Pellets

Enteric Coated (EC)	Composition W/W
Duloxetine	17%, 20%
Esomeprazole	8.5%, 22.5%, 30%
Esomeprazole (MUPS)	22.5%
Lansoprazole	8.5%
Omeprazole	7.5%, 8.5%
Pantoprazole	15%, 16%, 20%, 22%, 22.5%, 30%, 40%
Rabeprazole	10%, 15%, 20%

Immediate Release (IR)	
Domperidone	5.5%, 10%, 20%, 22.0%, 22.5%
Itraconazole	20%, 22%
Orlistat	50%

Sustained Release (SR)	
Diclofenac Sodium	40%
Domperidone	20%, 30%
Itopride HCl	60%
Levosulpiride	50%
Mebeverine HCl	80%
Tamsulosin HCl	0.2%, 0.12%, 0.16%

Under Development	Type	Composition W/W
Chlorpheniramine Maleate	SR	6.72%, 8%
Dabigatran Etxilate	IR	35%, 40%
Dexlansoprazole	DR	22.5%
Flurbiprofen	SR	60%
Ketoprofen	SR	60%
Levomilnacipran	SR	38.71%, 38.83%, 39.21%
Mesalamine	ER	60%
Metoprolol Succinate MUPS	SR	60%, 66%, 58%
Pancreatin Pellets	EC	60%, 70%
Peppermint oil Pellets	EC	23%
Venlafaxine	ER	33%

Percentage of the Pellets can be customised as per market requirements.

CUSTOM SYNTHESIS and CONTRACT MANUFACTURING

VPCL offers long term Contract Manufacturing services right from strategic partnerships in development, validations, DMF filing and commercial manufacturing of Active Pharmaceutical Ingredients (APIs) / advanced intermediates to APIs. We have flexible business models to support various client needs:

- Process optimisation, technology transfer, validations and DMF filing followed by manufacturing upon commercialization
- Technology absorption, validations, DMF filing support and commercial manufacturing
- Technology absorption and commercial manufacturing



Progress in Environmental, Health, Safety and Sustainability (EHS)



VASUDHA PHARMA CHEM LIMITED



- ISO 45001:2018 & ISO 14001:2015 Certified
- Achieved Bronze medal Rating By “EcoVadis”
- Implementing Process Safety Management (PSM) system
- EHS Audits as per the PSCI guidelines.
- Best management award by Telangana State Govt in 2016 & 2023.
- Best management award by Andhra Pradesh State Govt om 2018.
- Achieved “A” rating by A.P.Factories Department (Score:93.5/100).
- Clean & Green and Safety precautions award by state body (TSIIC – 2017, 2018 &2019)
- Continuously working on the Reduce, Reuse & Recycle policy.
- Achieved “C” rating by CDP (Carbon Disclosure Project) for 2023-24.
- Being regularly trained and nurtured on current EHS practises by top MNC’s.

VPCL Priorities

- Environment, Health and Wellness, Safety;
- Quality;
- Quantity.
- Sustainability

Environmental, Health & Safety

- VPCL is fully equipped with all kinds of necessary **Safety Equipment**.
- Periodic **Safety Training** programmes to all employees.
- **Occupational Health Centre** is equipped with all necessary medicines and equipment. Periodic **medical check-ups**.
- Personnel, trained on **First Aid**, are available in all the shifts.
- VPCL maintains **Green Belt** and plantation.
- VPCL actively encourages employees to meditate and celebrates world meditation day on 21st December every year.

EcoVadis Rating

- VPCL - I** : EcoVadis CSR rating - Bronze level
- VPCL - II** : EcoVadis CSR rating - Bronze level
- VPCL - III** : EcoVadis CSR rating - Bronze level
- VPCL - V** : EcoVadis CSR rating - Bronze level
- SRCCCL** : EcoVadis CSR rating - Bronze level





VASUDHA FOUNDATION

78 A, Vengalrao Nagar, HYDERABAD 500038 India

Tel : 0091 40 44763666 Fax : 0091 40 44763636

With a desire to serve the society and to help the needy, Vasudha Foundation, was founded by Mr. MANTENA VENKATA RAMA RAJU and his family members in the year 2004.



Objectives of VASUDHA FOUNDATION

- Educational and medical assistance
- Helping hand to specially abled people
- Welfare of orphan, down trodden, old age, ill-fated women and children.
- Immediate help to the people in crisis at the time of natural calamities

Carries out its services through the following programmes :

- Akshara** (Education) : Programme designed to extend helping hand to poor students pursuing higher education like engineering, medicine, post graduate courses & Vocation Skills Development etc.
- Aarogya** (Health) : Programme designed to provide financial assistance for medical treatment to the poor and needy.
- Aashraya** (Shelter) : Programme designed to address the problems faced by the senior citizens and taking care of them during their sacred phase of Vruddhapy life (old age)
- Aadarana** (Care & Rehabilitation) : Programme designed to enable specially abled people to face the challenges in life and lead a normal life.
- Akshaya** (Socio-economic development relief during natural calamities) : Contributions to the Prime Minister's National Relief Fund or any other Fund Set up by the Central Government of the State Government for Socio-economic development, relief, welfare etc. Programme designed to stand forefront to extend helping hand to the people effected by natural calamities.
- Aparigraha** : Ensuring environmental sustainability, ecological balance, Animal welfare, agro forestry and conservation of natural resources.
- Samskruti:** : Protection of National Heritage, Art & culture including setting up of public libraries, development of traditional arts and handicrafts. Promoting rural sports, national recognized sports and Olympic sports. Rural development projects. Supporting armed forces veterans, war widows and their dependants. Contributions to technology incubators approved by Central Government



Helping Students



Assistance to Seniors



Assistance to Old age home



Assistance to Old Age Home



Free Tailoring Training to women



Tailoring Machine's to poor women



Other Activities:

Planting saplings, Commissioning Water Purification Plants (600+) establishment of Schools, Colleges, Hospitals, Health Centers and Social Welfare Hostels, Promoting talent Arts & Sports, Providing training & distribution of Tailoring machine's to poor women.

AKSHARA ₹	AROGYA ₹	AASHRAYA & AADARANA ₹	AKSHAYA ₹	APARIGRAHA ₹	SAMSKRUTI ₹
1,33,97,500	1,30,35,004	88,18,120	12,00,000	4,75,000	22,35,000

*USD spent 2023-24 on the above programmes - \$ 470,888 (₹ 3,91,60,624)

Corporate Social Responsibility (CSR):

Enactment of Companies Act, 2013 by the Ministry of Corporate Affairs, Government of India was one of the world's largest experiments of introducing the CSR as a mandatory provision by imposing statutory obligation on Companies to take up CSR projects towards social welfare activities. The Corporate Social Responsibility (CSR) concept in India is governed by Section 135 of the Companies Act, 2013 ('Act'), Schedule VII of the Act and Companies (CSR Policy) Rules, 2014

As per National CSR Portal, VPCL is among the companies that spend more than the prescribed requirements mandated by the government.

Financial Year	Companies that fulfill CSR	Our Position from the Top
2022-23	13,571	401
2021-22	11,013	501
2020-21	9,935	576



(Sarve janah sukhino bhavanthu)

May everyone live happily

REGISTERED OFFICE:

78 A, Vengalrao Nagar, Hyderabad 500038, Telangana, India.

Phone : 0091-40-23711717

CORPORATE OFFICE:

Plot #: 120 and 121, 4th Floor, Jyothi Galaxy, Guttala Begumpet Village,
Kavuri Hills, Hyderabad 500033 Telangana, India.

Phone : 0091-40-4476 3666 / 2371 1718. Fax : 0091-40-4476 3636 / 2370 6696
Email ID : vasudha@vasudhapharma.com | Website : www.vasudhapharma.com

WORKS

- Unit I : Plot # 37/A, 38, 39 A & B, Phase I, IDA. Jeedimetla, Hyderabad-500055, Telangana, India
- Unit II : Plot # 79, Jawaharlal Nehru Pharma City, Parawada, Anakapalli-531019 A.P, India
- Unit III : Plot # 23, 24, Jawaharlal Nehru Pharma City, Parawada, Anakapalli-531019 A.P, India
- Unit IV : Plot # 1, Jawaharlal Nehru Pharma City, Parawada, Anakapalli-531019, A.P, India
- Unit V : Plot # 24, 24A & 24B, Atchutapuram, Rambili Mandal, Anakapalli-531011 A.P, India.

R&D CENTRE

Ramky Commercial Hub, Rd#13, JN Pharma City, Parawada,
Anakapalli-531019, Andhra Pradesh, INDIA.

www.vasudhapharma.com



MAY 2025

